Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer

Gynecol Oncol. 2005 Mar;96(3):902-5. doi: 10.1016/j.ygyno.2004.12.001.


Background: Angiogenesis is pivotal in the development and progression of ovarian cancer and is an ideal candidate for novel treatment approaches.

Case: A case of advanced, recurrent and refractory serous carcinoma is presented that responded to bevacizumab 15 mg/m2 intravenously every 3 weeks after failing eleventh line cytotoxic chemotherapy and radiation. An objective durable response lasting at least 5 months was documented.

Conclusion: Bevacizumab has activity in epithelial ovarian carcinoma and larger scale trials are indicated.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Female
  • Humans
  • Immunization, Passive / methods
  • Middle Aged
  • Ovarian Neoplasms / therapy*


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab